SCHEMBL548776

SCHEMBL548776

CCCCCCc1c(OCC2CO2)cc(OCC2CO2)c(C23CC4CC(CC(C4)C2)C3)c1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.37
GLA P06280 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
TP53 P04637 3/20 0.33
TSHR P16473 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HIF1A Q16665 2/20 0.33
CYP3A4 P08684 1/20 0.33
HSD11B1 P28845 1/20 0.33
CNR2 P34972 3/20 0.32
FAAH O00519 3/20 0.32
CNR1 P21554 1/20 0.32
PPARG P37231 2/20 0.32
PPARD Q03181 1/20 0.32
PPARA Q07869 1/20 0.32
ENPP2 Q13822 2/20 0.32
MAPT P10636 2/20 0.31
HPGD P15428 2/20 0.31
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL548945 0.86 ALDH1A1 (0.34) ALDH1A1GLATDP1TP53TSHR
SCHEMBL550093 0.83 ALDH1A1 (0.37) ALDH1A1GLATDP1SMN1; SMN2HSD11B1
SCHEMBL548793 0.81 ALDH1A1 (0.45) ALDH1A1GLATDP1TP53TSHR
SCHEMBL549873 0.81 ALDH1A1 (0.45) ALDH1A1GLATDP1TP53TSHR
SCHEMBL548896 0.79 ALDH1A1 (0.45) ALDH1A1GLATDP1TP53TSHR
SCHEMBL548880 0.79 ALDH1A1 (0.38) ALDH1A1GLATDP1TP53TSHR
SCHEMBL549920 0.78 ALDH1A1 (0.44) ALDH1A1GLATDP1TP53TSHR
SCHEMBL548813 0.77 ALDH1A1 (0.34) ALDH1A1TDP1TP53TSHRSMN1; SMN2
SCHEMBL550140 0.77 ALDH1A1 (0.43) ALDH1A1GLATDP1TP53TSHR
SCHEMBL549862 0.77 ALDH1A1 (0.43) ALDH1A1GLATDP1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110614-B2 Adamantane derivative, method for producing the same, and resin composition containing adamantane derivative IDEMITSU KOSAN CO., LTD. (JP) 2012-02-07 US disclosed
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2010-03-04 US disclosed
EP-2090563-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN COMPANY LIMITED (JP) 2009-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE ARCN1, RTN3, CHRNA3 ALDH1A1 312/4885GLA 1474/4885TDP1 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.